louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03843411: Mini-fluid Challenge as a Predictor of Fluid Response for Pneumoperitoneum Patient
Official title: Mini-fluid Challenge as a Predictor of Fluid Response for Pneumoperitoneum Patient
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Anesthesia
Keywords: mini-fluid challenge
Lead sponsor: Changhua Christian Hospital
Sponsor class: OTHER
First posted: 2019-02-18
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: receive operation that required pneumoperitoneum and FloTrac monitoring

Brief summary: The purpose of this study is to evaluate whether the change of stroke volume index(△SVI) induced by the rapid mini-fluid administration can predict fluid responsiveness in patients with pneumoperitoneum

Detailed description: Perioperative fluid management is significant important during surgery. The current trend tends to use goal-directed fluid therapy in surgery. Goal-directed fluid therapy refers to continuous monitoring of hemodynamic parameters during surgery and managing more accurate fluid administration based on the data obtained while promoting optimal tissue perfusion. Define fluid responsiveness with the hemodynamic parameters as to whether the cardiac output can be significantly increased after administration of fluid. Therefore, the advantage of predicting fluid responsiveness is that it can optimize the cardiac output and tissue perfusion while avoiding administering unnecessary fluid to patients.

The purpose of this study is to evaluate whether the change of stroke volume index(△SVI) induced by the rapid mini-fluid administration can predict fluid responsiveness in patients with pneumoperitoneum.

Eligibility criteria: Inclusion Criteria:

* receive operation that required pneumoperitoneum and FloTrac monitoring
* ASA 1\~3
* age between 20 to 70 year old

Exclusion Criteria:

* patient who cannot understand the process and aim of the study
* patient with arrhythmia
* poor heart function(LVEF\<50%, severe valvular disease, CAD)
* CKD
* pregnant patient
* patients allergic to voluven

Primary outcomes:
measure: change of stroke volume index
timeFrame: 1 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03657511: Tobacco Cessation Intervention
Official title: Educational Interventions to Promote Tobacco Cessation Among Women Seeking Mammography Screening
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking Tobacco
Keywords: Smoking
Lead sponsor: Barbara Ann Karmanos Cancer Institute
Sponsor class: OTHER
First posted: 2018-09-05
Enrollment: 100
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study is planned as an evaluation of a low cost, simple smoking cessation intervention. There is very little information about the effectiveness of a simple tobacco cessation strategy. Therefore, our objective is to obtain estimates of effectiveness that can be used to refine existing programs or to develop new ones.


Eligibility criteria: Inclusion Criteria:

* Able to understand and read English

Exclusion Criteria:

* Currently undergoing tobacco cessation treatment

Primary outcomes:
measure: The number of women who quit smoking in the last 12 weeks
timeFrame: 12 weeks after initial self-administered questionnaire
Secondary outcomes:
measure: The number of women who attempted to quit smoking in the last 12 weeks.
timeFrame: 12 weeks after initial self-administered questionnaire
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Barbara Ann Karmanos Cancer Institute
state: Michigan
Study officials:
References:
Clinical trial NCT05998811: Insights Into Participating in Studies for Uterine Cancer
Official title: Exploring Uterine Cancer Clinical Trials - Revealing Participation Patterns in Individuals With Uterine Cancer
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Uterine Cancer
Keywords: Uterine Cancer
Lead sponsor: Power Life Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2023-08-21
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Uterine cancer patients who are actively considering enrolling in a clinical trial for the said condition, but have not yet completed enrollment and randomization phases.

Brief summary: Clinical study participation has historically been heavily biased toward specific demographics.

Several people will be invited to enroll in this trial so that it may collect a variety of data about uterine cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.

People with uterine cancer who are invited to take part in medical study will benefit from the analysis of the data.


Eligibility criteria: Inclusion Criteria:

* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
* Diagnosis of uterine cancer
* No prior treatment for uterine cancer

Exclusion Criteria:

* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
* Enrolled in another research study
* Inability to provide written informed consent

Primary outcomes:
measure: Number of patients who decide to enroll in a uterine cancer clinical research
timeFrame: 3 months
measure: Rate of patients who remain in a uterine cancer clinical trial to trial completion
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Power Life Sciences
state: California
Study officials:
affiliation: Power Life Sciences Inc.
name: Michael B Gill
role: STUDY_DIRECTOR
References:
citation: Filippova OT, Leitao MM. The current clinical approach to newly diagnosed uterine cancer. Expert Rev Anticancer Ther. 2020 Jul;20(7):581-590. doi: 10.1080/14737140.2020.1782750. Epub 2020 Jun 22.
citation: Wang Z, Guo E, Yang B, Xiao R, Lu F, You L, Chen G. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer. Gynecol Oncol. 2021 Nov;163(2):358-363. doi: 10.1016/j.ygyno.2021.08.029. Epub 2021 Sep 8.
citation: Torres D, Myers JA, Eshraghi LW, Riley EC, Soliman PT, Milam MR. Risk factors for the development of uterine cancer in breast cancer survivors: an army of women study. Ann Surg Oncol. 2015;22(6):1974-9. doi: 10.1245/s10434-014-4193-5. Epub 2014 Nov 1.
Clinical trial NCT06873711: The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk of Ulcerative Colitis
Official title: The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk and Clinicopathological Characteristics of Ulcerative Colitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colitis, Ulcerative
Lead sponsor: Second Affiliated Hospital of Wenzhou Medical University
Sponsor class: OTHER
First posted: 2025-03-13
Enrollment: 926
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: There was no statistically significant difference in the gender ratio, average age, and proportion of smokers between UC group and normal control group. All study subjects are from the Zhejiang Han population who are not related by blood.

Brief summary: From January 2020 to December 2024, diagnosed ulcerative colitis(UC) patients and gender- and age-matched normal controls were enrolled from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Our aim is to investigate the associations of microribonucleic acid(miRNA) gene polymorphisms with the risk and clinicopathological characteristics of UC, and to analyze the effects of miRNAs gene variations on the clinical response of vedolizumab(VDZ) treatment in UC patients.

Detailed description: From January 2020 to December 2024, diagnosed UC patients and gender- and age-matched normal controls were enrolled from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. Genotypes of miRNAs were determined by multiplex polymerase chain reaction-ligase detection reaction technique. Chi-square test and unconditional logistic regression model were used to analyze the difference in distribution of miRNAs gene polymorphisms between UC group and normal control group, as well as the effects of miRNAs gene variations on the clinicopathological characteristics and 14-week clinical response to VDZ treatment of UC patients.

Eligibility criteria: Inclusion Criteria:

* diagnosed UC based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results

Exclusion Criteria:

* rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc.

Primary outcomes:
measure: Genotypes of miRNAs
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Wenzhou
country: China
facility: the Second Affiliated Hospital of Wenzhou Medical University
state: Zhejiang
Study officials:
References:
Clinical trial NCT06490211: The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors
Official title: The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Urinary System Carcinoma
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2024-07-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with urinary system tumors, including kidney cancer, bladder cancer, prostate cancer, etc.

Brief summary: Obtain puncture or surgically removed tumor tissue samples from patients with urinary tract tumors and perform RNA-sequencing, Single-cell RNA-sequence, Spatial Transcriptomics, Proteomics, and Intratumoral Microbiome.


Eligibility criteria: Inclusion Criteria:

1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026;
2. Aged \> 18 years old;
3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion Criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignant tumor other than urinary tract tumor;
4. Unclear pathological diagnosis

Primary outcomes:
measure: progression-free survival
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT05672693: Study on the Accuracy of Intraocular Lens Calculation Formula
Official title: Study on the Accuracy of Intraocular Lens Calculation Formula
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: the Accuracy of Intraocular Lens Calculation Formula
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-01-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who were previously diagnosed as "senile cataract" in the Ophthalmology Center of the Second Affiliated Hospital of Zhejiang University Medical College and who performed "phacoemulsification cataract extraction combined with intraocular lens implantation"

Brief summary: In this study, we will retrospectively collect patients who have performed phacoemulsification combined with intraocular lens implantation in our hospital, collect various preoperative biometric data and postoperative refractive data of patients, conduct statistical analysis, and compare the accuracy of various IOL calculation formulas.


Eligibility criteria: Inclusion Criteria:

* (1) Conform to the diagnosis of cataract; (2) No complications occurred during and after operation; (3) Before and after operation, the measurement of ocular biological characteristics and refractive state can be successfully completed; (4) Patients who can be followed up regularly after operation.

Exclusion Criteria:

* (1) Serious intraoperative or postoperative complications; (2) Complicated with other eye diseases unsuitable for intraocular lens implantation; (3) Patients with systemic diseases cannot tolerate surgery; (4) Patients with incomplete follow-up data.

Primary outcomes:
measure: Mean absolute error
timeFrame: 1 week、1 month and 3 months postoperation
Secondary outcomes:
measure: Distribution of error within ± 0.25D, ± 0.5D, ± 0.75D,and ± 1.0D
timeFrame: 1 week、1 month and 3 months postoperation
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Second Affiliated Hospital, Zhejiang University School of Medicine
state: Zhejiang
Study officials:
affiliation: Second Affiliated Hospital, Zhejiang University School of Medicine
name: Wen Xu
role: STUDY_CHAIR
References:
Clinical trial NCT01703793: Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
Official title: A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Seborrheic Dermatitis
Lead sponsor: Medicis Global Service Corporation
Sponsor class: INDUSTRY
First posted: 2012-10-11
Enrollment: 240
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if two test products are safe and effective in the treatment of seborrheic dermatitis.


Eligibility criteria: Inclusion Criteria:

* Investigator assessment of seborrheic dermatitis.
* Additional criteria as identified in the protocol.

Exclusion Criteria:

* History of or ongoing psoriasis of the scalp.
* History of or ongoing atopic dermatitis of the scalp.
* Additional criteria as identified in the protocol.

Primary outcomes:
measure: Symptom Improvement (investigator assessment)
timeFrame: Week 4
Secondary outcomes:
measure: Symptom Improvement (subject assessment)
timeFrame: Weeks 2 and 4
Other outcomes:
Locations:
city: Fremont
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: San Diego
country: United States
state: California
city: New Haven
country: United States
state: Connecticut
city: Aventura
country: United States
state: Florida
city: Augusta
country: United States
state: Georgia
city: Snellville
country: United States
state: Georgia
city: Evansville
country: United States
state: Indiana
city: Detroit
country: United States
state: Michigan
city: Fridley
country: United States
state: Minnesota
city: Paramus
country: United States
state: New Jersey
city: Mount Kisco
country: United States
state: New York
city: New York
country: United States
state: New York
city: High Point
country: United States
state: North Carolina
city: Portland
country: United States
state: Oregon
city: Philadelphia
country: United States
state: Pennsylvania
city: Arlington
country: United States
state: Texas
city: Austin
country: United States
state: Texas
city: College Station
country: United States
state: Texas
city: Plano
country: United States
state: Texas
city: Webster
country: United States
state: Texas
city: Salt Lake City
country: United States
state: Utah
Study officials:
affiliation: Medicis Pharmaceutical
name: Ira Lawrence, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01715493: Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom
Official title: Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom: a Randomised Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Obstructive Pulmonary Disease
Asthma
Keywords: COPD
Asthma
Lysozyme Hydrochloride
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2012-10-29
Enrollment: 48
Sex: ALL
Minimum age (years): 20
Maximum age (years): 84
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study was to assess the effectiveness for small airway inflammation of 4 weeks lysozyme administration in Chronic Obstructive Pulmonary Disease (COPD) and/or asthma.


Eligibility criteria: Inclusion criteria:

For COPD:

* Over 20 years of age and below 85 years of age
* Smoking history
* Brinkman index 200 or more
* Diagnosis of COPD
* Forced expiratory volume in 1 second (FEV1) of \<80% of the predicted value
* Ratio of FEV1 to forced vital capacity (FVC) of \<70%
* symptom of expectorated sputum

For Asthma

* Over 20 years of age and below 85 years of age
* Scored between 20 to 24 by ACT (Asthma Control Test)
* Symptom of expectorated sputum
* Diagnosed partly controlled by global initiative for asthma

Exclusion criteria:

* Egg allergy
* Domiciliary oxygen therapy
* Pneumonia or pulmonary tuberculosis
* Patients with severe cardiovascular disorder, severe kidney disorder, severe hepatic disorder, severe hematological disorder
* Cancer

Primary outcomes:
measure: Change of several inflammatory or biochemical marker concentration in inducted sputum
timeFrame: 8 weeks (2 periods each lasting 4 weeks)
measure: Peripheral airway resistance and reactance measured by Impulse oscillometry system, and NO concentration.
timeFrame: 8 weeks (2 periods each lasting 4 weeks)
Secondary outcomes:
measure: Monthly reduction in forced expiratory volume in 1 Second (FEV1)
timeFrame: 8 weeks (2 periods each lasting 4 weeks)
measure: Quality of life assessed by CAT (COPD Assessment Test) and ACT (Asthma Control Test)
timeFrame: 8 weeks (2 periods each lasting 4 weeks)
Other outcomes:
Locations:
city: Mizunami
country: Japan
state: Gifu
Study officials:
affiliation: Drug Fostering and Evoluation Coordination Department, Corporate Regulatory Compliance, Safety and Quality Assurance Headquaters
name: Kai Shibata
role: STUDY_DIRECTOR
References:
Clinical trial NCT03822793: A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty
Official title: Dose Study of Tranexamic Acid in Total Hip Replacement to Reduce Post-operative Hemoglobin Loss: A Phase 2 Randomized Double-blind Monocentric Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Arthropathy of Hip
Keywords: tranexamic acid (TXA)
arthroplasty
hip
Exacyl
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2019-01-30
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A single preoperative dose of tranexamic acid (TXA) reduces blood loss and red blood cell transfusion in primary hip arthroplasty. Numerous regimens have been tested, ranging from 10mg/kg up to 3g. However the optimal dose to administer is unknown.

Detailed description: This dose-response study is a randomized double blind study with five groups of 30 patients each. Patients will be randomized to placebo, tranexamic acid (TXA) 300 mg, tranexamic acid (TXA) 500 mg, tranexamic acid (TXA) 1000 mg or tranexamic acid (TXA) 3000 mg. In addition a pharmacokinetic/pharmacodynamic study will be performed to identify the contribution of tranexamic acid (TXA) plasma concentration as a predictor of intra and postoperative D-Dimer values.

Eligibility criteria: Inclusion Criteria:

* Patient requiring primary hip arthroplasty (less than 3 months)
* Informed Consent from the patient or their legally authorized representative
* Affiliation to French Social Security Healthcare system

Exclusion Criteria:

* Hip fracture of less than 3 months
* Bilateral hip arthroplasty or anterior approach to hip arthroplasty
* Haemorrhagic surgery in the previous 2 weeks
* Contraindication to tranexamic acid
* Contraindication to apixaban
* Chronic use of anticoagulant
* Pregnancy
* Previous participation to this study

Primary outcomes:
measure: haemoglobin decrease in the perioperative period
timeFrame: Day 1 to Day 8
Secondary outcomes:
measure: Tranexamic acid pharmacokinetics
timeFrame: Day 1
measure: D-Dimer kinetics
timeFrame: Day 1
measure: allogenic red blood cell transfusion
timeFrame: Day 1 to day 8
measure: severe anaemia
timeFrame: Day 1 to day 8
measure: incidence of symptomatic thrombotic events and death
timeFrame: Day 1 to day 8
measure: occurrence of a seizure
timeFrame: Day 8
measure: number of adverse events
timeFrame: Day: 45
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: CHU Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Julien LANOISELEE, MD
role: PRINCIPAL_INVESTIGATOR
References: